• In mid-May 2026, Encompass Health Corp. completed a US$500,000,000 private offering of 5.875% senior unsecured notes due 2034 and moved to redeem US$400,000,000 of its 4.500% senior notes due 2028 at par, expecting a US$3,200,000 loss on early extinguishment of debt.
• This refinancing, alongside plans for a new 50-bed inpatient rehabilitation hospital in Post Falls, Idaho opening in 2028, reshapes the company’s capital structure while supporting continued expansion of its rehabilitation network.
• We’ll now examine how Encompass Health’s US$500,000,000 senior notes refinancing and Idaho hospital expansion affect its existing growth-focused investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Encompass Health Investment Narrative Recap

To own Encompass Health, you need to believe the company can keep filling its growing rehabilitation footprint while managing labor costs and regulatory exposure. The new US$500,000,000 notes and partial redemption of 2028 debt modestly reshape its balance sheet but do not meaningfully change the near term focus on staffing pressures as the key risk or on execution of new hospital openings as the main catalyst.

The most immediate link to this story is the planned 50 bed Post Falls, Idaho hospital, which fits directly into the company’s de novo growth pipeline. Together with the recent bond refinancing, it shows Encompass Health aligning its funding and build out schedule, but investors still need to watch how capital intensive expansion interacts with reimbursement trends and wage inflation.

Yet investors should be aware that sustained de novo build outs could pressure free cash flow if...

Encompass Health's narrative projects $7.4 billion revenue and $769.8 million earnings by 2029. This requires 7.9% yearly revenue growth and about a $204.1 million earnings increase from $565.7 million today.

Uncover how Encompass Health's forecasts yield a $142.73 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Four Simply Wall St Community fair value estimates for Encompass Health span about US$99 to US$167 per share, underlining very different views on upside. Against that backdrop, the latest US$500,000,000 refinancing and continued bed expansion bring the question of capital intensity and future returns on new hospitals into sharper focus for you as a shareholder.

Explore 4 other fair value estimates on Encompass Health - why the stock might be worth 6% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Encompass Health research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Encompass Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Encompass Health's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.